Piper Sandler Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Sciences (NASDAQ:GILD) had its price target raised by equities research analysts at Piper Sandler from $105.00 to $110.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price objective would suggest a potential upside of 3.81% from the company’s current price.

GILD has been the subject of several other research reports. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Truist Financial raised their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Finally, Bank of America reissued a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $101.33.

Gilead Sciences Trading Up 2.6 %

Shares of Gilead Sciences stock opened at $105.96 on Wednesday. The firm has a market cap of $132.05 billion, a price-to-earnings ratio of 1,177.33, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $106.43. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The business has a 50-day moving average price of $93.38 and a 200-day moving average price of $87.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Equities research analysts anticipate that Gilead Sciences will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 710,500 shares of company stock worth $67,684,956 in the last three months. 0.16% of the stock is owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds have recently made changes to their positions in GILD. nVerses Capital LLC acquired a new position in Gilead Sciences during the 3rd quarter valued at about $25,000. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. Valued Wealth Advisors LLC increased its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences during the 4th quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. acquired a new position in Gilead Sciences during the 4th quarter valued at about $29,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.